Ad
related to: astrazeneca stock- thinkorswim®
Access The Award-Winning Platform
Built By Traders, For Traders.
- Pricing for Online Trades
No Account Fees or Platform Fees
With Schwab's Trading Services.
- Start Trading Today
Open Your Brokerage Account With
Schwab For No Trade Minimums.
- Trader Education
Explore Our Education Library To
Get From "How?" to "Know-How."
- thinkorswim®
Search results
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 2 days agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 1 day agoThe institutional investor owned 1,390,959 shares of the company’s stock after buying an additional 95,652 shares during the period. First Trust Advisors LP’s holdings in ...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 4 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 5 days agoTrading at 18 times its expected future earnings, the stock's valuation is attractive when compared to the average healthcare stock, which trades at a...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 2 days agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 2 days agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Cramer's Lighting Round: 'You've got a winner' with Astra Zeneca
CNBC· 7 days ago"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 2 days agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
InvestorPlace· 1 day agoThis however holds true for high-quality blue-chip and growth stocks. On the other hand, in an...